Tenderwize
Back to tender search

Open-house rebate agreements for Natalizumab IV

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Mar 31, 2027 · 226 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Natalizumab, i.v. Darreichungsform, ATC L04AG03

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Why this score?

Opportunity

46 / 100

Complexity

58 / 100

Risk factors

Submission must be in original form and electronic submission is not allowed.

Only authorised and marketable medicines in Germany may be supplied; if Lauer-Taxe evidence is missing, additional AMIc...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Supply of pharmaceutical products under an open-house rebate agreement for Natalizumab, intravenous dosage form, ATC L04AG03.
  • Non-exclusive contract model with uniform terms for all participants; no individual negotiations.
Show full summary

Open-house supply arrangement for Natalizumab (IV form, ATC L04AG03) offered by AOK Rheinland-Pfalz/Saarland. The notice states this is a non-exclusive, open-house model with uniform terms, no individual negotiations, and monthly entry possible during a maximum 24-month period. Submission is by original documents, electronic submission is not allowed, and the provided data indicates no contract value was published. The notice also states that children’s medicines listed by BfArM under §35(5a) SGB V are excluded.

Risks

Submission must be in original form and electronic submission is not allowed.

Only authorised and marketable medicines in Germany may be supplied; if Lauer-Taxe evidence is missing, additional AMIc...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Only authorised and marketable medicines in Germany may be supplied under the contract.

Administrative

  • If the medicine is not listed in Lauer-Taxe at submission time, the bidder must provide an extract from the public AMIce database and, where needed, additional supporting...
  • Submission must be in original form; electronic submission is not allowed.

Buyer

Lots (1)

LOT-0001

Open-house rebate agreements for Natalizumab IV

Single lot covering non-exclusive open-house rebate agreements for medicinal products containing Natalizumab in intravenous dosage form (ATC L04AG03). The buyer states that all interested pharmaceutical companies may join under identical conditions, without selection decision or individual negotiation. The lot excludes medicines listed as children’s medicines under the BfArM list referenced in the notice. Contract duration is up to 24 months, with the earliest start on 2025-06-01 and monthly entry possible; contracts end no later than 24 months after the earliest start date. The lot-level value is not provided.

SuppliesEU fundedElectronic submission

Location

Eisenberg, Germany

Duration

May 2025 - May 2027

Category

Pharmaceutical products

Deadline

Deadline Mar 31, 2027

Procurement Details

Publication date
10 Apr 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
235853-2025

Documents (1)

Similar tenders